

company announcement

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 23 June 2014 – On 1 May 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2014.

Under the programme initiated 1 May 2014, Novo Nordisk will repurchase B shares for an amount up to DKK 4.0 billion in the period from 1 May 2014 to 5 August 2014.

Since the announcement as of 16 June 2014, the following transactions have been made under the programme:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	6,986,000		1,649,582,799
16 June 2014	225,000	250.06	56,263,523
17 June 2014	250,000	254.57	63,643,650
18 June 2014	265,000	254.89	67,544,949
19 June 2014	250,000	252.78	63,195,375
20 June 2014	270,000	253.82	68,531,589
Accumulated under the programme	8,246,000		1,968,761,885

With the transactions stated above, Novo Nordisk owns a total of 26,706,394 B shares of DKK 0.20, corresponding to 1.0% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2014. As of 20 June 2014, Novo Nordisk has

Novo Nordisk A/S Investor Relations Novo Allé 2880 Bagsværd Denmark
 Telephone:
 CVR no:

 +45 4444 8888
 24 25 67 90

 Internet:
 www.novonordisk.com

 Company announcement No 39 / 2014

repurchased a total of 23,679,995 B shares equal to a transaction value of DKK 5,673,450,021.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 40,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information

+45 4442 3450	amhg@novonordisk.com
+45 3079 4303	<u>krop@novonordisk.com</u>
+45 3079 8519	<u>jlis@novonordisk.com</u>
+45 3079 6376	<u>dabo@novonordisk.com</u>
+1 609 235 8567	fdni@novonordisk.com
	+45 3079 4303 +45 3079 8519 +45 3079 6376

Novo Nordisk A/S Investor Relations Novo Allé 2880 Bagsværd Denmark Telephone:CVR+45 4444 888824 2Internet:24 2www.novonordisk.com2014Company announcement No 39 / 2014

CVR no: 24 25 67 90